How excluding some benefits from value assessment of new drugs impacts innovation

Joseph P. Cook and Joseph Golec

Health Economics, 2017, vol. 26, issue 12, 1813-1825

Abstract: Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently exclude some drugs' option‐related benefits, reducing their reimbursement chances, and making them less attractive R&D investments. We develop and test a real options model of R&D investment that shows that excluding option‐related benefits heightens drug developers' incentives to avoid high‐risk (volatile) R&D investments and instead encourages them to focus on “safer” (positively skewed) investments. Our model and empirical results could partly explain the decline in the number of risky new molecular entities.

Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.3507

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:26:y:2017:i:12:p:1813-1825

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().